Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
To read the full story
Related Article
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
April 25, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
September 2, 2021
BUSINESS
- Shoichiro Ogawa to Lead Sun Pharma Japan
April 2, 2025
- Alper Alptekin Becomes Japan President of Organon
April 2, 2025
- GE Healthcare Fully Acquires Nihon Medi-Physics
April 1, 2025
- Ono Pairs Up with Reborna to Discover CNS Disease Drugs
April 1, 2025
- Chugai CEO’s Pay Tops 400 Million Yen in 2024: Securities Report
April 1, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…